Building on striking phase 2 data which showed mean body weight reductions of approximately 24% at the highest dose over 48 weeks retatrutide simultaneously targets GLP-1, GIP, and glucagon receptors, potentially offering a more powerful metabolic effect than existing treatments
However, the authors stress that caution remains appropriate for a small, specific group
The April 30, 2026 FDA proposal would further close the 503B bulks pathway permanently
Though its intended purpose is to moderate insulin levels in diabetics, new users are overwhelmingly adopting the drug for its notable weight loss side effects
And at Waverley Oaks, you dont have to go it alone
Some doctors might offer GLP-1 medications like Ozempic to fix this, but at Ovafit, we take a different approach